• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Study Ignites Controversy Over Trazodone and Suicide

Study Ignites Controversy Over Trazodone and Suicide

May 7, 2020
Eugene Rubin, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Eugene Rubin, MD. Dr. Rubin has disclosed that he has no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Review of: Lavigne JE et al, J Gen Intern Med 2019;34(8):1554–1563


Study Type: Observational comparative safety study


Trazodone is one of the most widely prescribed sleep aids in the US despite lacking FDA approval for insomnia. But what if patients taking trazodone attempted suicide at a rate over 1.5 times that of those taking zolpidem (Ambien)? Lavigne and colleagues arrived at this potentially alarming conclusion in their observational safety study.


The authors mined data from the Department of Veterans Affairs (VA) to compare the rate of suicide attempts in veterans treated with various sedative-hypnotics, including trazodone, zolpidem, hydroxyzine, and benzodiazepines. Close to 350,000 patients met study criteria. The authors matched the patients in terms of psychiatric and medical comorbidities, inpatient days, disability ratings, concomitant medications, and several other variables. To control for other confounding variables, they used a “propensity score,” which is an estimate of the likelihood that a given patient would be prescribed zolpidem. This process resulted in four groups of about 75,000 patients divided according to type of sleep medication.


The primary endpoint was suicide attempts as detected in medical records. The rate of attempts was higher only when the trazodone group (n = 57) was compared to zolpidem (n = 38), a 61% increase in attempts. There was no mention of completed suicides.


Before you take your patients off trazodone, remember that observational studies have some glaring limitations. Despite the use of sophisticated statistics, it is impossible to control for all confounding factors. In this study, the authors acknowledge that they did not control for nightmares, and trazodone was a first-line treatment for nightmares in this population. This is an important confound, because the trazodone group may have already been at higher risk of suicide due to greater symptomatic distress. Although the authors controlled for comorbidities, it’s still possible that physicians were more likely to prescribe trazodone than zolpidem to patients with signs of addiction or impulsivity.


The analysis also failed to account for drug interactions. This is important because CYP2D6 inhibitors can increase levels of the trazodone metabolite, m-chlorphenylpiperazine (mCPP). Abrupt increases in this metabolite, which can happen when a CYP2D6 inhibitor is introduced, have been linked to dysphoria and anxiety, as well as to self-harm in adolescents (Shamseddeen W et al, J Child Adolesc Psychopharmacol 2019;29(7):573).


TCPR’s Take
While the apparent association of trazodone with suicidality raises concern, the study does not prove causation and may illustrate that nightmares and possibly drug interactions correlate with suicide attempts in a population of veterans. Prospective controlled trials in varied populations are needed before making recommendations against the use of trazodone.

General Psychiatry
KEYWORDS hypnotics research-update suicidality trazodone
Eugene Rubin, MD.

Buspirone: Still Effective After All These Years?

More from this author
www.thecarlatreport.com
Issue Date: May 7, 2020
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Telepsychiatry, TCPR, May 2020
In Brief
Trazodone: The Forgotten Antidepressant
Telepsychiatry: From Crisis to Opportunity
A Potentially Lethal Side Effect You Probably Never Heard Of
Study Ignites Controversy Over Trazodone and Suicide
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.